Business Context and Reporting Period
Company: Ascendis Pharma A/S
Filing Type: Form 20-F (Annual Report)
Reporting Period: Fiscal year ended December 31, 2016
Business Overview: Ascendis Pharma is a clinical-stage biopharmaceutical company developing sustained-release prodrug therapies using its proprietary TransCon technology. The company has no approved products and generates revenue primarily through collaboration agreements, license fees, and research services. Its lead product candidate, TransCon human Growth Hormone (hGH), is in Phase 3 clinical trials for pediatric growth hormone deficiency.
Key Financial Metrics
| Metric (EUR '000) | 2016 | 2015 |
|---|---|---|
| Revenue | 4,606 | 8,118 |
| Research & Development Costs | (66,022) | (40,528) |
| General & Administrative Expenses | (11,504) | (9,415) |
| Operating Loss | (72,920) | (41,825) |
| Net Loss | (68,505) | (32,922) |
| Cash and Cash Equivalents (Year End) | 180,329 | 119,649 |
| Total Equity | 176,613 | 120,329 |
| Operating Cash Flow | (60,179) | (43,466) |
| Financing Cash Flow | 117,462 | 105,742 |
Debt and Liquidity: The company reported no interest-bearing debt as of December 31, 2016. Total liabilities were EUR 13.5 million. Liquidity is supported by cash reserves of EUR 180.3 million, bolstered by a follow-on public offering in late 2016 that raised approximately EUR 116.6 million in net proceeds.
Material Changes vs. Prior Period
- Revenue Decline: Revenue decreased 43% to EUR 4.6 million in 2016 from EUR 8.1 million in 2015. This was primarily due to a EUR 2.7 million decrease in revenue from the Genentech collaboration (due to extended recognition periods and fewer services) and a EUR 0.5 million decrease from the Sanofi collaboration.
- Increased R&D Spend: Research and development costs increased 63% to EUR 66.0 million. The increase was driven by EUR 10.2 million in external costs for TransCon hGH manufacturing and Phase 3 trial preparation, as well as increased personnel costs.
- Widening Net Loss: Net loss more than doubled to EUR 68.5 million from EUR 32.9 million, reflecting the surge in R&D expenses and lower revenue.
- Exchange Rate Impact: Net finance income decreased to EUR 4.2 million (from EUR 8.3 million in 2015) due to less significant positive exchange rate fluctuations between the U.S. Dollar and Euro compared to the prior year.
Guidance, Outlook, and Risks
Outlook and Milestones:
- TransCon hGH: Initiated the pivotal Phase 3 "heiGHt" trial in August 2016 for pediatric growth hormone deficiency. Recruitment is expected to complete in Q4 2017.
- TransCon PTH: Plans to file an Investigational New Drug (IND) application in Q2 2017 for hypoparathyroidism.
- TransCon CNP: Plans to file an IND application in Q4 2017 for achondroplasia.
- Capital Requirements: Management believes existing cash reserves are sufficient to meet projected requirements for at least 12 months from the report date. However, the company expects to require substantial additional financing in the future to support clinical development and commercialization.
Key Risks and Contingencies:
- Clinical Failure: As a clinical-stage company with no approved products, the business is highly dependent on the success of its Phase 3 and planned Phase 1 trials. Failure to meet primary endpoints could halt development.
- Collaboration Dependence: Revenue and future milestones depend on partners (Sanofi, Genentech) successfully developing and commercializing products. Partners have the right to terminate agreements for convenience or breach.
- Regulatory Uncertainty: The company relies on expedited regulatory pathways (e.g., FDA Section 505(b)(2)) which are not guaranteed. Regulatory authorities may require additional trials or reject applications.
- Manufacturing: The company relies entirely on third-party contract manufacturers for clinical and future commercial supplies.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the EUR 180.3 million cash balance against the projected burn rate for the Phase 3 heiGHt trial and upcoming IND filings.
- Revenue Recognition: Review the deferred income balance (EUR 0.1 million as of 2016) and the specific terms of the Sanofi and Genentech agreements to understand future revenue visibility.
- Clinical Trial Progress: Monitor enrollment rates and interim data for the Phase 3 heiGHt trial, as this is the primary catalyst for valuation.
- Share-Based Compensation: Note the significant non-cash expense of EUR 7.3 million in 2016 related to share-based payments, which impacts net loss but not cash flow.
- Foreign Exchange Exposure: Assess the impact of USD/EUR fluctuations on future financial statements, given the company holds significant USD cash reserves but incurs expenses in EUR and DKK.